Contineum Therapeutics, Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024. Contineum is a clinical-stage biopharmaceutical company developing oral small-molecule therapies for neuroscience, inflammation and immunology conditions. It had no approved products and reported no product or license revenue in the quarter.
Financial performance and liquidity
| Metric | Q1 2024 | Q1 2023 |
|---|---|---|
| Revenue | None reported | None reported |
| Research and development expense | $7.8 million | $3.6 million |
| General and administrative expense | $2.2 million | $1.5 million |
| Total operating expenses | $9.9 million | $5.1 million |
| Net loss | $8.4 million | $4.8 million |
| Basic and diluted net loss per share | $3.55 | $2.12 |
| Cash used in operating activities | $8.0 million | $5.2 million |
At March 31, 2024, cash and cash equivalents were $16.3 million and marketable securities were $101.6 million, totaling $117.9 million. Current assets were $119.7 million and current liabilities were $6.2 million. Total liabilities were $6.6 million; the filing reports no outstanding loan principal, while operating lease liabilities remained. The company had an accumulated deficit of $83.6 million. No operating margin is meaningful because there was no quarterly revenue.
Changes versus the prior comparable period
- Operating expenses increased $4.8 million, or about 94%, and net loss increased $3.6 million, or about 74%, year over year.
- R&D expense rose $4.1 million, primarily reflecting higher clinical research costs for PIPE-307 and PIPE-791, PIPE-791 toxicology work and personnel costs. G&A increased $0.7 million, mainly due to consulting costs associated with public-company audit requirements.
- Interest income increased to $1.6 million from $0.4 million, reflecting higher invested funds and yields. The company recorded a $0.1 million non-cash expense from remeasuring its preferred-stock warrant liability; interest expense was zero, versus $0.1 million in Q1 2023.
- Operating cash use increased by $2.7 million. Investing cash inflow was $8.7 million, mainly from marketable-security sales and maturities exceeding purchases.
Business outlook, risks and notable events
- PIPE-791: The wholly owned candidate is being developed for idiopathic pulmonary fibrosis and progressive multiple sclerosis. After completing a Phase 1 healthy-volunteer trial, the company planned to submit a UK clinical trial application in 2024 for a Phase 1b open-label PET study to inform dosing for planned Phase 2 trials.
- PIPE-307: The company is funding a Phase 2 RRMS trial under its agreement with Johnson & Johnson (J&J), which holds an exclusive worldwide license for the candidate. J&J has announced plans to start a Phase 2 depression trial in 2024 and retains discretion over further development. Contineum may receive up to approximately $1.0 billion in contingent milestones and tiered royalties, but no such contingent amounts were recognized in Q1 2024.
- Pipeline and spending: CTX-343, a peripherally restricted LPA1R antagonist, was nominated in January 2024 and entered preclinical work. Management expects R&D and G&A spending to increase substantially as trials, research, staffing and public-company costs expand. The filing provides no quantified earnings or revenue guidance.
- Runway and financing: The company said cash, cash equivalents and marketable securities, together with IPO proceeds, were expected to fund operations for at least 12 months from the filing. Its April 2024 IPO and partial over-allotment generated approximately $108.0 million in net proceeds. Runway estimates depend on clinical timelines, costs and other assumptions; additional funding may be needed, and financing could dilute shareholders or require granting rights to programs.
- Other subsequent events: A 1-for-5.5972 reverse stock split took effect April 1, 2024. The IPO closed in April, and preferred stock converted into common stock. These events occurred after quarter-end and are not reflected in the March 31 balance sheet. As of May 15, the company reported 18,994,104 Class A and 6,729,172 Class B shares outstanding.
- Principal risks: Both lead candidates remain in early clinical development; trial results, safety, enrollment, regulatory acceptance and timing are uncertain. The company depends on CROs and contract manufacturers, including a sole China-based manufacturer of PIPE-791 API. J&J may discontinue PIPE-307 development or terminate its agreement. The company also cites IP, competition, reimbursement, financing and public-company execution risks. It reported no material legal proceedings and said disclosure controls were effective.
Investor facts to verify
- Progress, enrollment and timing for the planned PIPE-791 Phase 1b study and Phase 2 programs, and the ongoing PIPE-307 RRMS trial; distinguish company plans from completed milestones.
- J&J’s development plans for PIPE-307, including the announced depression trial, and the conditions and likelihood of future milestones and royalties.
- How the $108.0 million IPO net proceeds and quarterly cash burn affect actual runway as trial spending and public-company costs rise.
- Post-IPO share count, preferred-stock conversion, dual-class voting rights, and potential dilution from options and future financing.
- The filing’s cover page indicates the company checked “No” for having filed all required Exchange Act reports during the preceding 12 months; verify the reporting-history context and any implications.